Back Hepatitis B Hepatitis B Topics HBV Disease Progression

AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring

Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.alt

Read more:

AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising

The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients. alt

Read more:

HBV Genotype Affects Hepatitis B Disease Progression and Outcomes

Hepatitis B virus (HBV) genotype influences long-term outcomes including viral clearance, according to a Swedish study reported in the May 18, 2012, advance edition of the Journal of Clinical Virology. Genotype C in particular appears to be associated with more aggressive disease.alt

Read more:

AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?

When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. alt

Read more:

Researchers Shed Light on how Hepatitis B Virus Causes Liver Cancer

Hepatitis B virus (HBV) is more often integrated in liver tumor cells than normal liver tissue cells, and multiple integrations may be linked to more aggressive disease progression and poorer survival, researchers reported in the May 27, 2012 advance online edition of Nature Genetics.alt

Read more:

Researchers Grow Liver Tissue from Pluripotent Stem Cells

Japanese researchers have produced liver-like tissue from induced pluripotent stem cells in the laboratory that can process drugs like a human liver, according to a presentation at the 10th annual meeting of the International Society for Stem Cell Research last week in Yokohama.alt

Read more:

EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more: